CSL share price on watch amid US$1.6b profit

CSL has been battling currency headwinds during the half but still delivered a solid result…

| More on:
A doctor appears shocked as he looks through binoculars on a blue background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL has released its half year results this morning
  • The biotherapeutics giant has delivered a US$1.6 billion profit
  • Management has reaffirmed its full year profit guidance

The CSL Limited (ASX: CSL) share price will be one to watch on Tuesday.

This follows the release of the biotherapeutics giant's eagerly anticipated half year results.

CSL share price on watch following results release

  • Total revenue up 19% to US$7,183.5 million
  • Net profit after tax down 8% to US$1,623.2 million
  • Net profit after tax before amortisation (NPATA) in constant currency up 10% to US$1,957 million
  • Interim dividend up 2.9% to US$1.07 per share

What happened during the half?

For the six months ended 31 December, CSL reported a 19% increase in total revenue to US$7,183.5 million.

This was driven by the acquisition of Vifor Pharma, strong growth in immunoglobulin and albumin sales, record levels of plasma collections, strong growth in market leading haemophilia B product Idelvion and key specialty product Kcentra, and a strong performance by influenza vaccines business, CSL Seqirus.

And while CSL's profits were down 8% to US$1,623.2 million, this was in line with consensus estimates and due to currency headwinds and acquisition costs. This was largely.

NPATA on a constant currency basis provides a better reflection of the company's performance. That was up 10% year over year to US$1,957 million.

Management commentary

CSL's outgoing CEO, Paul Perreault, commented:

CSL delivered a solid performance in the first half of the financial year demonstrating the strong fundamentals of the company and the disciplined execution of our patient focused strategy. Our focused investment across our business units underpinned our resilience throughout the pandemic, and as we emerge from it we are starting to deliver positive momentum behind our sustainable growth agenda.

Outlook

Management is expecting more of the same in the second half. As a result, it has reaffirmed its guidance for FY 2023 NPATA in the range of approximately US$2.7 billion to US$2.8 billion at constant currency. Perreault added:

The strong growth we have seen in plasma collections and our immunoglobulins franchise is expected to continue. We are looking forward to launching Hemgenix in the US, an exciting, ground breaking, new therapy that will change people's lives. The rest of our R&D pipeline is in great shape and we look forward to bringing more innovative therapies to patients in the future.

Seqirus continues to perform strongly and will deliver another profitable year. Consistent with the seasonal nature of the business we anticipate, however, a loss in the second half of the year. The integration of CSL Vifor is well advanced and we will focus on driving organic growth and efficiencies across the product portfolio and deliver on our synergy objectives

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »